Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34
J. Clin. Invest. Dengshun Miao, et al. 115:2402 doi:10.1172/JCI24918 [Go to this article.]

Figure 2
Generation of Pthrp^flox/flox;cre^ColI mice. (A) Decalcified paraffin sections stained histochemically for HPAP activity. HPAP activity was detected only in preosteoblasts and osteoblasts in Z/AP;cre^ColI mice but not in Z/AP mice. (B) Genomic organization of WT and floxed Pthrp alleles as well as changes in the restriction enzyme pattern anticipated following digestion of tail-tip genomic DNA with BamHI and hybridization with a 0.65-kb SacI/XhoI genomic DNA fragment as probe (–). Arrowheads represent loxP sequences flanking exon 3. (C) Floxed Pthrp allele and Cre transgene detected by Southern blot analysis of tail-tip genomic DNA. The flox/flox–Cre-positive mice comprised the Pthrp^flox/flox;cre^ColI experimental group, while the Pthrp^flox/flox mice were controls. (D) Decalcified paraffin sections immunostained for PTHrP. PTHrP immunoreactivity (red arrowheads) was seen in growth plate chondrocytes of Pthrp^flox/flox;cre^ColI mice and control mice but in preosteoblasts and osteoblasts only in control mice. Magnification, ×400.